Elanco Animal 医疗

US · ELAN #1381 按市值排名上市于 2018

23.55 +0.01 +0.04%

实时 - 追踪5344个代码 - 心跳于357秒前 · 2026-10-16 20:02

✦ 量化股权信号计算方式说明

涨跌不一/平稳

最近一期（2026/Q3）披露持股的机构数量增加了1家。
机构持股总比例基本持平。

机构持股

机构持股比例: 114.23% -0.08pp
机构数量: 604 +1
数据截至: 2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund102.09%

Hedge Fund6.81%

Public Company2.83%

Government Pension Fund1.04%

Individual/Insider0.71%

Private Company0.70%

Insurance Company0.28%

Family Office/Trust0.25%

Government0.13%

主要股东截至 2026-06-30

Dodge & Cox 13.49% · 67.40M 股

FMR 9.91% · 49.52M 股

BlackRock 9.78% · 48.85M 股

PRIMECAP Management Company 9.10% · 45.45M 股

T. Rowe Price Group, Inc. 6.03% · 30.13M 股

Vanguard Capital Management, LLC 5.16% · 25.77M 股

Dimensional Fund Advisors 5.09% · 25.42M 股

Vanguard Portfolio Management, LLC 4.54% · 22.67M 股

State Street Global Advisors 3.22% · 16.06M 股

Winslow Capital Management, LLC 2.70% · 13.51M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 49次买入 · 1次卖出

姓名	职务	持股比例
Jeffrey Simmons	Chief Executive Officer	0.37%
Ramiro Cabral	Executive VP & President of Elanco International	0.04%
Ellen de Brabander	Executive Vice President of Innovation, Regulatory & Business Development	0.04%
David Kinard	Executive Vice President of Human Resources, Corporate Communications & Administration	0.04%
Roy Hoover	Independent Chairperson	0.04%
Rajeev Modi	Executive Vice President of U.S. Pet Health & Global Digital Transformation	0.03%
Timothy Bettington	Executive Vice President of Corporate Strategy & Market Development	0.02%
Grace McArdle	Executive Vice President of Manufacturing & Quality	0.02%
Shiv O'Neill	Interim Executive VP, General Counsel & Corporate Secretary	0.02%
Todd Young	Chief Financial Officer	0.02%

内部人交易最近的 Form 4 申报记录

日期	姓名	职务	类型	股数	价格
2026-09-29	Kapila Anand	Independent Director	Other Derivative Acquisition	+642	--
2026-09-17	Jeffrey Simmons	Chief Executive Officer	Other Derivative Acquisition	+126	--
2026-09-17	Robert VanHimbergen	Chief Financial Officer	Other Derivative Acquisition	+8	--
2026-09-17	Rajeev Modi	Executive Vice President of U.S. Pet Health & Global Digital Transformation	Other Derivative Acquisition	+65	--
2026-09-03	Jeffrey Simmons	Chief Executive Officer	Other Derivative Acquisition	+115	--
2026-09-03	Robert VanHimbergen	Chief Financial Officer	Other Derivative Acquisition	+8	--
2026-09-03	Rajeev Modi	Executive Vice President of U.S. Pet Health & Global Digital Transformation	Other Derivative Acquisition	+60	--
2026-08-20	Jeffrey Simmons	Chief Executive Officer	Other Derivative Acquisition	+117	--
2026-08-20	Robert VanHimbergen	Chief Financial Officer	Other Derivative Acquisition	+8	--
2026-08-20	Rajeev Modi	Executive Vice President of U.S. Pet Health & Global Digital Transformation	Other Derivative Acquisition	+61	--
2026-08-19	Lawrence Kurzius	Independent Director	Open Market Acquisition	+40,000	$23.40
2026-08-17	Shiv O'Neill	Interim Executive VP, General Counsel & Corporate Secretary	Open Market Acquisition	+3,998	$23.58
2026-08-11	Michael Harrington	Independent Director	Open Market Acquisition	+5,000	$21.82
2026-08-06	Paul Herendeen	Independent Director	Open Market Acquisition	+10,000	$23.69
2026-08-06	Jeffrey Simmons	Chief Executive Officer	Other Derivative Acquisition	+127	--
2026-08-06	Robert VanHimbergen	Chief Financial Officer	Open Market Acquisition	+4,200	$23.08
2026-08-06	Robert VanHimbergen	Chief Financial Officer	Other Derivative Acquisition	+8	--
2026-08-06	Rajeev Modi	Executive Vice President of U.S. Pet Health & Global Digital Transformation	Other Derivative Acquisition	+66	--
2026-07-23	Jeffrey Simmons	Chief Executive Officer	Other Derivative Acquisition	+113	--
2026-07-23	Robert VanHimbergen	Chief Financial Officer	Other Derivative Acquisition	+7	--

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 20:02:14 · 仅供参考，不构成投资建议，也未考虑您的具体情况。